Table 2.
Association between TLR3 expression, clinical characteristics, and overall survival (OS) of 194 NSCLC patients.
| Hazard ratio (HR) | 95% confidence Iimit (CI) | P valuea | |
|---|---|---|---|
| TLR3-tb-positive | 0.630 | 0.397–1.001 | 0.0503 |
| TLR3-sc-positive | 1.618 | 1.032–2.535 | 0.0359 |
| TLR3-ic-positive | 1.380 | 0.884–2.155 | 0.1567 |
| Histology adenocarcinoma | 0.641 | 0.418–0.981 | 0.0405 |
| pT 2, 2a | 1.408 | 0.920–2.155 | 0.1154 |
| Age ≥60 | 2.223 | 1.148–4.304 | 0.0178 |
| BMI ≥25 | 1.240 | 0.810–1.899 | 0.3218 |
| Male gender | 3.876 | 1.940–7.742 | 0.0001 |
| Smoker | 2.644 | 1.067–2.644 | 0.0357 |
OS was defined as the time between the date of surgery and the date of death from any cause or the date of the last follow-up. Univariate survival analysis was carried out by phreg procedure using a Cox regression model and the determination of the statistical significance of all categorical predictors by chi-square test. The effects of explanatory variables on event hazard were quantified by hazard ratios (HR)33. All analyses were conducted using SAS (SAS 9.4 Institute Inc., Cary, NC, USA).
aCox regression analysis.
bScore of TLR3-t expression: percentage of positive tumor cells ≥3.
cScore of TLR3-s and TLR3-i expression: percentage of positive immune cells ≥1.